Translational studies of new treatments for movement disorders, including phase II and phase IIII clinical studies.
Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
Mov Disord. 2018 Oct;33(10):1560
Mov Disord Clin Pract. 2018 Jan-Feb;5(1):66-74
Ann Neurol. 2018 Oct 24;:
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
Eur J Neurosci. 2018 Sep 30;:
Neuropharmacology. 2018 Jun 01;:
Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
Parkinsonism Relat Disord. 2018 May 05;:
Curr Opin Neurol. 2018 May 08;:
Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden.
Front Aging Neurosci. 2018;10:120
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Mov Disord. 2018 Mar 23;:
Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.
CMAJ. 2018 Jan 15;190(2):E50-E52